Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Quoin Pharmaceuticals Ltd. (QNRX) is the issuer whose shares are covered by ownership reports from StemPoint Capital LP, StemPoint Capital Management GP LLC and Michelle Ross; each may be deemed to beneficially own 506,983 American Depositary Shares (ADS), or 9.9% of the class.
The ownership calculation uses 4,804,161 ADS outstanding as of September 16, 2026, and includes shares acquirable under warrants subject to a 9.99% beneficial ownership limitation. It excludes 107,762 ADS underlying pre-funded warrants.
Key Figures
Beneficial ownership:506,983 ADSPercent of class:9.9%ADS outstanding:4,804,161 ADS+3 more
6 metrics
Beneficial ownership506,983 ADSEach reporting person may be deemed to beneficially own this amount.
Percent of class9.9%Reported beneficial ownership for each reporting person.
ADS outstanding4,804,161 ADSAs of September 16, 2026; used in the ownership calculation.
Beneficial ownership limitation9.99%Limitation applicable to the warrants.
ADS excluded from calculation107,762 ADSADS underlying pre-funded warrants excluded from the ownership calculation.
Ordinary shares per ADS35 ordinary shares per ADSEach ADS represents thirty-five ordinary shares.
Key Terms
American Depositary Shares, Pre-Funded Warrants, Beneficial Ownership Limitation, Rule 13d-3(d)(1)(i)
4 terms
American Depositary Sharestechnical
"American Depositary Shares, each representing thirty-five (35) Ordinary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Pre-Funded Warrantsfinancial
"shares of ADS through the exercise of a pre-funded warrant"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Beneficial Ownership Limitationregulatory
"subject to the Beneficial Ownership Limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
Rule 13d-3(d)(1)(i)regulatory
"in accordance with Rule 13d-3(d)(1)(i) under the Act"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many QNRX ADS do the reporting persons beneficially own?
StemPoint Capital LP, StemPoint Capital Management GP LLC and Michelle Ross may each be deemed to beneficially own 506,983 ADS, reported as 9.9% of the class.
What ownership limit applies to QNRX warrants?
The warrants are subject to a 9.99% beneficial ownership limitation. The ownership calculation excludes 107,762 ADS underlying pre-funded warrants and uses 4,804,161 ADS outstanding as of September 16, 2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Quoin Pharmaceuticals Ltd.
(Name of Issuer)
American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share
(Title of Class of Securities)
74907L409
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
74907L409
1
Names of Reporting Persons
StemPoint Capital LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
506,983.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
506,983.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
506,983.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
74907L409
1
Names of Reporting Persons
StemPoint Capital Management GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
506,983.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
506,983.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
506,983.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: StemPoint Capital Management GP LLC is a limited liability company.
SCHEDULE 13G
CUSIP Number(s):
74907L409
1
Names of Reporting Persons
Michelle Ross
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
506,983.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
506,983.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
506,983.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Quoin Pharmaceuticals Ltd.
(b)
Address of issuer's principal executive offices:
42127 Pleasant Forest Court, Ashburn, VA 20148-7349
Item 2.
(a)
Name of person filing:
This filing is being jointly filed by StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons" and each a "Reporting Person").
(b)
Address or principal business office or, if none, residence:
The business addresses of each Reporting Person is:
520 Madison Avenue, 19th Floor
New York, NY 10022
(c)
Citizenship:
StemPoint Capital LP is a limited partnership organized under the laws of the State of Delaware.
StemPoint Capital Management GP LLC is a limited liability company organized under the laws of the State of Delaware.
Michelle Ross is a citizen of the United States of America.
(d)
Title of class of securities:
American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share
(e)
CUSIP Number(s):
74907L409
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Items 5-9 of each cover page are incorporated by reference. Each Reporting Person may be deemed to be the beneficial owner of 506,983 shares of American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share ("ADS"), consisting of consisting of (i) 236,234 shares of ADS, (ii) 173,596 shares of ADS through the exercise of a pre-funded warrant (the "Pre-Funded Warrants"), and (iii) 97,153 shares of Common Stock underlying warrants (with the Pre-Funded Warrants, the "Warrants"). The Warrants are subject to a beneficial ownership limitation of 9.99% (the "Beneficial Ownership Limitation").
(b)
Percent of class:
Each Reporting Person may be deemed to beneficially own 9.9% shares of ADS, which is calculated based on (i) 4,804,161 ADS outstanding as of September 16, 2026, as disclosed in the Issuer's prospectus filed with the Securities and Exchange Commission on September 25, 2026, plus (i) 173,596 shares of ADS which may be acquired upon the exercise of the pre-funded warrants, and (ii) 97,153 shares of ADS which may be acquired upon the exercise of underlying warrants which are subject to the Beneficial Ownership Limitation, which amount has been added to the shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act. The foregoing excludes 107,762 shares of ADS underlying the Pre-Funded Warrants, which is subject to the Beneficial Ownership Limitation. Due to field limitations of the EDGAR filing system, the percentages listed in Row 11 of the Reporting Persons' cover pages have been rounded down to 9.9%.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
-0-
(ii) Shared power to vote or to direct the vote:
506,983. Comment: Shared voting power includes 270,749 Warrants beneficially owned by the Reporting Persons.
(iii) Sole power to dispose or to direct the disposition of:
-0-
(iv) Shared power to dispose or to direct the disposition of:
506,983. Comment: Shared dispositive power includes 270,749 Pre-Funded Warrants beneficially owned by the Reporting Persons.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.